Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX

Oct.22.2025
Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
VOZOL has listed a new product, NEON PLUG MAX, on its official website, featuring dual 2 ml prefilled pods and dual 10 ml refill bottles (24 ml total), a claimed maximum of 36,000 puffs, and two-flavour switching. The device was previously shown at InterTabac 2025 and was listed by the UK MHRA in March 2025; however, as of publication it was not yet available on overseas retail sites.

Special statement:

This article is for internal industry communication only and does not make any recommendations for specific brands or products.

The images presented in this article are only used to describe the facts and are not intended as advertisements for any products.

Minors are prohibited from accessing this article.


Product Highlights

 

  • “2×2+10” capacity layout: dual 2 ml transparent prefilled pods + dual 10 ml refill bottles, with visible liquid level.
  • Rated 36,000 puffs: claimed up to 36k puffs in “ECO” mode, equivalent to roughly 1,500 puffs per ml.
  • Dual-flavour switch: lift the top cap and rotate 180° to toggle between two flavours.
  • Endurance & display: built-in 1,000 mAh battery, side mini-screen for battery and puff mode.
  • Progress & compliance: shown at InterTabac 2025; MHRA database indicates the model has been listed.

2Firsts, 22 October 2025 — 2Firsts notes that e-cigarette brand VOZOL has unveiled the NEON series newcomer NEON PLUG MAX on its official website. The device adopts a 2× “2 ml prefilled pod + 10 ml refill bottle” configuration, with an official claim of up to 36,000 puffs and a 1,000 mAh battery. It supports two-flavour switching and includes a compact display. The product was showcased during InterTabac 2025 in Dortmund.

 

 

36,000 puffs • 1,000 mAh battery

 

 

2Firsts has compiled the key specifications of the VOZOL NEON PLUG MAX, as summarised in the table below:

 

Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
VOZOL NEON PLUG MAX Specifications | Graphic: 2Firsts

 

From the specifications, VOZOL NEON PLUG MAX uses a 2× “2+10” architecture, pairing two 2 ml prefilled pods with two 10 ml refill bottles. In ECO mode it claims a total of 36,000 puffs, which converts to 1,500 puffs per ml, aligning with the performance previously noted by 2Firsts for the SKE 30K Pro Max.

 

Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
VOZOL NEON PLUG MAX with “2×2+10” design | Source: VOZOL official website

 

The 2 ml prefilled pod portion uses a transparent design so users can directly see the e-liquid level.

 

According to the official site, the product features a flip-over design: simply lift the top cap and rotate 180° to switch flavours. The current showcase includes five body colours and 30 flavour pairings, mainly “fruit × fruit” and “fruit × icy” combinations.

 

Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
Selected colours and flavours of VOZOL NEON PLUG MAX | Source: VOZOL official website

 

For endurance, the NEON PLUG MAX integrates a 1,000 mAh battery, and a small side display shows the battery level and puff mode.

 

 

Shown at InterTabac; listed by MHRA

 

 

At InterTabac 2025 (Dortmund), the 2Firsts team had already spotted the VOZOL NEON PLUG MAX on site. As of publication, 2Firsts had not observed any overseas retail listings for this product; on Instagram, VOZOL’s official account has posted a product launch teaser.

 

Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
VOZOL NEON PLUG MAX at InterTabac 2025 | Source: 2Firsts

 

Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
VOZOL official launch teaser posted on Instagram | Source: Instagram

 

2Firsts’ check of the UK Medicines and Healthcare products Regulatory Agency (MHRA) notification database shows that “NEON PLUG MAX Electronic cigarette device” was submitted on 21 March 2025 by SHENZHEN FORESIGHT INNOVATIONS TECHNOLOGY CO., LTD. (Shenzhen Zhiyuan Zhichuang Technology Co., Ltd.) and has been listed. The product has passed compliance review and obtained permission for legal sale in the UK.

 

Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
“NEON PLUG MAX Electronic cigarette device” listing information | Source: MHRA

As a leading global NGP media and think tank, 2Firsts is dedicated to providing the latest product and technological information and insights to practitioners around the world in various categories such as e-cigarettes, heated tobacco products, and modern oral products. It aims to drive technological changes and innovations in NGP products worldwide, thereby offering tobacco consumers globally with safer products and lifestyles.
 
With a source of information covering the supply chains in China and global markets, 2Firsts product coverage has become one of the most influential platforms for new product and technology releases globally.
 
Contact 2Firsts for the following services:  

1. Providing leads on new products and technologies; 
2. Offering comments on products and technologies;  

3. Seeking media coverage for your products;  

4. Identifying sales channels for products.
 
Contact Information: Email: info@2firsts.com
 
Contact CEO Alan Zhao of 2Firsts on LinkedIn.
 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's liquid-vape market is showing changes across raw-material imports, product types and sales channels after synthetic nicotine came under the Tobacco Business Act on April 24. Customs data show nicotine-analogue imports totaled 12,126 kilograms from April through August, while synthetic-nicotine imports over the same five months totaled 231,663 kilograms, just 39.3% of the amount imported in March alone. Physical liquid-vape stores tracked in Seoul and Gyeonggi Province fell 9.9%, unmanned outlets edged higher and online sales listings increased from 27,774 to 42,437. Government testing of 105 liquid inhalation products promoted as nicotine-free separately found nicotine in 13 and 6-methylnicotine in 12.
Sep.22
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11